HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 05-25-2014, 10:46 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post New ASCO Guidelines Address HER2-Positive Breast Cancer

New ASCO Guidelines Address HER2-Positive Breast Cancer

Laurie Barclay, MD
May 07, 2014

Most patients with advanced HER2-positive breast cancer should receive HER2-targeted drugs. But which of the several targeted agents available should be used, and in which order?
A new evidence-based guideline from the American Society of Clinical Oncology (ASCO), published online May 5 in the Journal of Clinical Oncology, addresses those issues.
The purpose of the clinical practice guideline is to provide oncologists and other clinicians with evidence-based recommendations on systemic therapy for patients with HER2-positive advanced breast cancer, write Sharon H. Giordano, from the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues. They note that HER2-positive tumors account for about 15% of all breast cancer, although some estimates put that figure at around 25%.
In particular, say the authors, the rationale for the new guideline was to provide recommendations on use of the targeted agents that have been approved in recent years. After the first HER2-targeted therapy trastuzumab (Herceptin) was launched in 1998, lapatinib (Tykerb) and more recently pertuzumab (Perjeta) and ado-trastuzumab emastine, also known as TDM-1 (Kadcyla), entered the market.
The guideline is based on a systematic review of literature published from January 2009 to October 2012 that addressed overall survival, progression-free survival, and adverse events.
Among the 16 trials meeting the inclusion criteria was the CLEOPATRA trial, which showed that overall and progression-free survival improved after first-line treatment with docetaxel, trastuzumab, and pertuzumab. In another, the EMILIA trial, overall and progression-free survival improved after second-line treatment with T-DM1, and progression-free survival improved after third-line treatment with T-DM1.
Specific Recommendations for Patients With Advanced HER2-Positive Breast Cancer
Most patients should receive HER2-targeted therapy (evidence quality, high; recommendation, strong)
Patients with clinical congestive heart failure or significantly compromised left ventricular ejection fraction should be evaluated for HER2-targeted therapy on an individual basis, as should those with estrogen receptor (ER)-positive or progesterone receptor (PgR)-positive tumors (evidence quality, high; recommendation, strong)
First-line treatment should be trastuzumab, pertuzumab, and taxane, unless the patient has a contraindication to taxanes (evidence quality, high; recommendation, strong)
Patients who completed trastuzumab-based adjuvant treatment more than 12 months before recurrence should follow the recommendations for first-line HER2-targeted therapy (evidence quality, high; recommendation, strong)
Patients who completed trastuzumab-based adjuvant treatment 12 months or less before recurrence should follow the recommendations for second-line HER2-targeted therapy (evidence quality, intermediate; recommendation, moderate)
Patients who progress during or after first-line HER2-targeted treatment should receive second-line HER2-targeted treatment with T-DM1 (evidence quality, high; recommendation, strong)
Patients who progress during or after second-line or greater HER2-targeted therapy should receive third-line or greater HER2-targeted therapy (evidence quality, intermediate; recommendation, moderate)
Patients who progress during or after second-line or greater HER2-targeted therapy can be offered T-DM1 as third-line treatment if they have not previously received it (evidence quality, high; recommendation, strong)
Patients who progress during or after second-line or greater HER2-targeted therapy can be offered pertuzumab as third-line treatment if they have not previously received it (evidence quality, insufficient; recommendation, weak)
Patients who progress during or after second-line or greater HER2-targeted therapy who have already received T-DM1 and pertuzumab can be offered other HER2-targeted therapy combinations, such as lapatinib plus capecitabine, as well as other combinations of chemotherapy, and trastuzumab, lapatinib, and trastuzumab, or hormonal therapy (in patients with ER-positive and/or PgR-positive disease) (evidence quality, insufficient; recommendation, weak)
Optimal duration of chemotherapy for patients receiving HER2-targeted therapy is 4 to 6 months or until maximum response, depending on toxicity and the absence of progression. When chemotherapy is stopped, HER2-targeted therapy should continue with no further changes until progression or unacceptable toxicity (evidence quality, intermediate; recommendation, moderate)
Patients with HER2-positive and ER- or PgR-positive breast cancer can receive standard first-line treatment (evidence quality, high; recommendation, strong); for select patients, endocrine therapy plus HER2-targeted therapy (evidence quality, high; recommendation, moderate) or endocrine therapy alone (evidence quality, intermediate; recommendation, weak) can be appropriate


Expert Consensus Guidelines for Patients With Brain Metastases
Accompanying consensus-based recommendations address the management of patients with advanced HER2-positive breast cancer who develop brain metastases. Because of the lack of clinical trial evidence, these recommendations are based mainly on expert consensus.
This guideline is needed, in some measure, because of the success of HER2-targeted therapy, which has improved survival for patients with early-stage and metastatic breast cancers, write Naren Ramakrishna, MD, PhD, from the University of Florida Health Cancer Center at Orlando Health, and colleagues. However, they note, HER2 positivity is a known risk factor for the development of brain metastases.
The systematic literature review did not identify sufficiently strong evidence, so the expert panel used a modified Delphi process and a formal process based on expert consensus to generate draft recommendations. The original panel and another group of experts subjected the draft recommendations to 2 rounds of formal ratings.
Final Recommendations for Patients With Advanced HER2-Positive Breast Cancer and Brain Metastases
Because patients with HER2-positive advanced breast cancer have a high incidence of brain metastases, clinicians should have a low threshold for brain MRI on the basis of symptoms or history of brain metastases, but should not routinely perform MRI to screen for brain metastases
For patients whose systemic disease is not progressive when brain metastasis is diagnosed, systemic therapy should not be switched
Patients with progressive systemic disease when brain metastasis is diagnosed should receive HER2-targeted therapy in accordance with the recommendations for HER2-positive metastatic breast cancer
Patients should receive appropriate local therapy and systemic therapy, if indicated, on the basis of prognosis, symptoms, resectability, number and size of metastases, previous treatment, and nature of metastases (diffuse vs focal)
For patients with a favorable prognosis for survival and a single brain metastasis or 2 to 4 brain metastases, appropriate local therapy includes surgery with postoperative radiation, whole-brain radiotherapy (WBRT), fractionated stereotactic radiotherapy, and/or stereotactic radiosurgery; these patients should be monitored after treatment with serial imaging every 2 to 4 months
Patients with a more favorable prognosis despite diffuse disease or extensive metastases, those with symptomatic leptomeningeal brain metastasis, and those with poor prognosis can be offered WBRT
Other management interventions can include systemic therapy, best supportive care, clinical trial enrollment, and/or palliative care
Some of the guideline authors report various financial relationships with Esteva, Genentech, Novartis, Roche, AstraZeneca, Pfizer, GlaxoSmithKline, Brainlab Ag Research Funding, Bristol-Myers Squibb, Synta Pharmaceuticals, Array Biopharma, and Geron.
J Clin Oncol. Published online May 5, 2014. Breast cancer abstract, Breast cancer and brain metastases abstract

http://www.medscape.com/viewarticle/824751#1
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes

Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"

Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla

Reconstruction: TRAM flap, partial loss, Revision

The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease

Last edited by 'lizbeth; 05-25-2014 at 10:48 AM.. Reason: reference link added
'lizbeth is offline   Reply With Quote
Old 05-26-2014, 03:13 AM   #2
Aussie Girl
Senior Member
 
Aussie Girl's Avatar
 
Join Date: Jul 2013
Posts: 260
Re: New ASCO Guidelines Address HER2-Positive Breast Cancer

Hi 'lizbeth

If you know how, would you make that post a "sticky" because it is good to have new guidelines posted somewhere easy to access.

Aussie Girl
__________________
31mm Infiltrating duct carcinoma
Grade 3, ER/PR-, HER2+, Neg Sentinel nodes x 5
49mm field of DCIS
17 June '13: Screen detected impalpable mass, Mammogram neg, US.
25 June '13: Diagnosed after multiple biopsies and MRIs
28 June '13: Left lumpectomey
4 July '13: Left Mastectomy
12 August '13: Commenced TCH chemo
Mid December '13 : TCH finished. Herceptin continuing three weekly.
4 August 2014- Herceptin infusions finished.
END OF THERAPY - YAY!
Aussie Girl is offline   Reply With Quote
Old 05-26-2014, 02:05 PM   #3
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: New ASCO Guidelines Address HER2-Positive Breast Cancer

AussieGirl,

I am not sure about making a sticky post. Perhaps someone else knows about function?
'lizbeth is offline   Reply With Quote
Old 06-27-2014, 03:12 AM   #4
Jackie07
Senior Member
 
Jackie07's Avatar
 
Join Date: Jan 2008
Location: "Love never fails."
Posts: 5,802
Post Re: New ASCO Guidelines Address HER2-Positive Breast Cancer

Perhaps you can do it via editing?
__________________
Jackie07
http://www.kevinmd.com/blog/2011/06/doctors-letter-patient-newly-diagnosed-cancer.html
http://www.asco.org/ASCOv2/MultiMedi...=114&trackID=2

NICU 4.4 LB
Erythema Nodosum 85
Life-long Central Neurocytoma 4x5x6.5 cm 23 hrs 62090 semi-coma 10 d PT OT ST 30 d
3 Infertility tmts 99 > 3 u. fibroids > Pills
CN 3 GKRS 52301
IDC 1.2 cm Her2 +++ ER 5% R. Lmptmy SLNB+1 71703 6 FEC 33 R Tamoxifen
Recc IIB 2.5 cm Bi-L Mast 61407 2/9 nds PET
6 TCH Cellulitis - Lymphedema - compression sleeve & glove
H w x 4 MUGA 51 D, J 49 M
Diastasis recti
Tamoxifen B. scan
Irrtbl bowel 1'09
Colonoscopy 313
BRCA1 V1247I
hptc hemangioma
Vertigo
GI - > yogurt
hysterectomy/oophorectomy 011410
Exemestane 25 mg tab 102912 ~ 101016 stopped due to r. hip/l.thigh pain after long walk
DEXA 1/13
1-2016 lesions in liver largest 9mm & 1.3 cm onco. says not cancer.
3-11 Appendectomy - visually O.K., a lot of puss. Final path result - not cancer.
Start Vitamin D3 and Calcium supplement (600mg x2)
10-10 Stopped Exemestane due to r. hip/l.thigh pain OKed by Onco 11-08-2016
7-23-2018 9 mm groundless(granules?) nodule within the right lower lobe with indolent behavior. Due to possible adenocarcinoma, Recommend annual surveilence.
7-10-2019 CT to check lung nodule.

"I WANT TO BE AN OUTRAGEOUS OLD WOMAN WHO NEVER GETS CALLED AN OLD LADY. I WANT TO GET SHARP EDGED & EARTH COLORED, TILL I FADE AWAY FROM PURE JOY." Irene from Tampa

Advocacy is a passion .. not a pastime - Joe
Jackie07 is offline   Reply With Quote
Old 07-10-2014, 09:54 AM   #5
Jackie07
Senior Member
 
Jackie07's Avatar
 
Join Date: Jan 2008
Location: "Love never fails."
Posts: 5,802
Post Re: New ASCO Guidelines Address HER2-Positive Breast Cancer

This short Video also has positive info on Her2 breast cancer. http://www.medpagetoday.com/HOTTOPIC...are-Videos/654
__________________
Jackie07
http://www.kevinmd.com/blog/2011/06/doctors-letter-patient-newly-diagnosed-cancer.html
http://www.asco.org/ASCOv2/MultiMedi...=114&trackID=2

NICU 4.4 LB
Erythema Nodosum 85
Life-long Central Neurocytoma 4x5x6.5 cm 23 hrs 62090 semi-coma 10 d PT OT ST 30 d
3 Infertility tmts 99 > 3 u. fibroids > Pills
CN 3 GKRS 52301
IDC 1.2 cm Her2 +++ ER 5% R. Lmptmy SLNB+1 71703 6 FEC 33 R Tamoxifen
Recc IIB 2.5 cm Bi-L Mast 61407 2/9 nds PET
6 TCH Cellulitis - Lymphedema - compression sleeve & glove
H w x 4 MUGA 51 D, J 49 M
Diastasis recti
Tamoxifen B. scan
Irrtbl bowel 1'09
Colonoscopy 313
BRCA1 V1247I
hptc hemangioma
Vertigo
GI - > yogurt
hysterectomy/oophorectomy 011410
Exemestane 25 mg tab 102912 ~ 101016 stopped due to r. hip/l.thigh pain after long walk
DEXA 1/13
1-2016 lesions in liver largest 9mm & 1.3 cm onco. says not cancer.
3-11 Appendectomy - visually O.K., a lot of puss. Final path result - not cancer.
Start Vitamin D3 and Calcium supplement (600mg x2)
10-10 Stopped Exemestane due to r. hip/l.thigh pain OKed by Onco 11-08-2016
7-23-2018 9 mm groundless(granules?) nodule within the right lower lobe with indolent behavior. Due to possible adenocarcinoma, Recommend annual surveilence.
7-10-2019 CT to check lung nodule.

"I WANT TO BE AN OUTRAGEOUS OLD WOMAN WHO NEVER GETS CALLED AN OLD LADY. I WANT TO GET SHARP EDGED & EARTH COLORED, TILL I FADE AWAY FROM PURE JOY." Irene from Tampa

Advocacy is a passion .. not a pastime - Joe

Last edited by Jackie07; 07-10-2014 at 09:55 AM.. Reason: See how to add a tag ...
Jackie07 is offline   Reply With Quote
Old 07-10-2014, 10:21 AM   #6
jaykay
Senior Member
 
Join Date: Oct 2012
Posts: 621
Re: New ASCO Guidelines Address HER2-Positive Breast Cancer

Thanks , 'Lizbeth. I did notice the omission of early-stage Her2+ breast cancer. Early stage meaning Stages 1-2.

Have you run across any new recommendations for that?

Best
Janis
__________________
March, 2000: 48, Post menopausal (5 yrs HRT) Left breast, IDC 3mm/DCIS 1.6cm, ER+/PR-/Her2+++, mod differentiated, MIB low, lumpectomy, node neg via SNB, rads=33 Stage 1a
June, 2000: Tamox 4.5 years,Femara for 5 years (end in Jan. 2010)
Sept, 2012: 61, Via mamm, ultrasound, biopsy, right breast, 2.3cm tumor, ER+/PR-/Her2+++, poorly diff, KI67 60-70%
BRCA 1 and 2 negative
October, 2012: Bi Mast with tissue expanders, port placement
Final Path: IDC 2.8cm, DCIS, 1/4 sentinal nodes positive (@#$%). Stage IIB
Nov 29, 2012: Begin TCH/6x/every 3 wks, H for 1 year/every 3 weeks.
March 14, 2013: Finished chemo
April 9, 2013: Begin radiation 28x
May 22, 2013: Finished rads
June 1st, 2013: Started Aromasin for 5 yrs.
July 15, 2013: Switched to Letrozole (Femara). Probably for the rest of my life
October 16, 2013: Exchange surgery
October 31, 2013: Finished Herceptin
December 5, 2013: Port removed
Glad this year is over!
jaykay is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 02:29 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter